Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CG Oncology, Inc. (CGON)

CG Oncology says President and COO Ambaw Bellete will leave June 30, 2026

Neutral Impact 4 of 5 leadership Written later

CG Oncology agreed on May 20, 2026 to the separation of President and Chief Operating Officer Ambaw Bellete, effective June 30, 2026. Arthur Kuan was appointed President in addition to his existing roles, and the company has started a search for a Chief Commercial Officer, which matters to shareholders because it changes senior leadership and the executive team responsible for commercial operations.

Key points

  • Ambaw Bellete, President & Chief Operating Officer, separation effective June 30, 2026
  • Separation agreement expected to include a general release and the severance set forth in Section 4(b) of his employment agreement
  • Arthur Kuan appointed President on May 20, 2026, in addition to his other positions
  • Company has initiated a search for a Chief Commercial Officer

The filing

CompanyCG Oncology, Inc. (CGON)
Form8-K, current report
Filed with the SECMay 26, 2026, 8:00 AM ET
Accession number0001193125-26-237908

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.